Pulmozyme revenue trends
Roche’s (RHHBY) Pulmozyme reported revenues of 357.0 million Swiss francs in the first half compared to 352.0 million Swiss francs in the first half of 2017, reflecting ~3% YoY growth at CER (constant exchange rates). In the first half, in the US and Europe markets, Pulmozyme generated revenues of 239.0 million Swiss francs and 67.0 million Swiss francs, respectively.
In the first half in the US market, Pulmozyme witnessed an ~1% decline. In the European markets, Pulmozyme’s first-half revenues remained flat. In the second quarter, Pulmozyme generated revenues of 188.0 million Swiss francs, which reflected ~6% YoY growth at CER.
Pulmozyme is commonly used for the treatment of individuals with cystic fibrosis. In the cystic fibrosis drugs market, Pulmozyme’s peers include Vertex Pharmaceuticals’ (VRTX) Orkambi, Kalydeco, and Symdeko. Orkambi, Kalydeco, and Symdeko generated revenues of $253.0 million, $311.0 million, and $186.0 million, respectively, in the second quarter.
CellCept revenue trends
Roche’s CellCept generated revenues of 333.0 million Swiss francs in the first half compared to 346.0 million Swiss francs in the first half of 2017, which reflected an ~6% YoY decline at CER.
In the first half in the United States, Europe, and Japan, CellCept generated revenues of 54.0 million Swiss francs, 90.0 million Swiss francs, and 38.0 million Swiss francs, respectively, reflecting an ~16% decline, an ~5% decline, and 5% growth on a YoY basis at CER.
In the second quarter, CellCept reported revenues of 175.0 million Swiss francs, which reflected an ~4% YoY decline.
CellCept (mycophenolate mofetil) is used for the prevention of organ rejection in patients undergoing allogeneic renal, hepatic, or cardiac transplant. In the marketplace, Novartis’s (NVS) Myfortic is CellCept’s peer. Myfortic generated revenues of $378.0 million in fiscal 2017. The sales of Myfortic are expected to decline in 2018 due to loss of exclusivity in different markets.